Argos Nears Phase III Results For Precision Cancer Immunotherapy
Executive Summary
With pivotal data expected in 2017 in metastatic kidney cancer, Argos hopes its drug will bridge the hot points of immuno-oncology and personalized medicine with a drug that extract’s RNA from a patient’s tumor and primes the dendritic cells to teach the immune system how to kill the cancer.
You may also be interested in...
Argos Not Stopping Cancer Vaccine Study Despite Futility
The biotech suggests that ADAPT trial design was not ideally structured to show the longer-term benefit that might result from its autologous immunotherapy. Argos plans to discuss its plan with FDA in May, despite analyst skepticism.
Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments
Argos mum on details surrounding Phase III failure of rocapuldencel-T in kidney cancer, while Agenus distances itself from failed Phase II glioblastoma study of Prophage G-200 as an investigator-sponsored trial with a challenging design.
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.